Development of Solid Lipid Nanoparticles for Praziquantel Delivery: Particle Size Characterization and Cell Toxicity Assessment
Excerpt
Praziquantel (PZQ) is a drug active against all species of Schistosoma and it is the drug of choice for the treatment of schistosomiasis [1]. [...]
Share and Cite
SOUZA, A.L.R.; ANDREANI, T.; DOKTOROVOVÁ, S.; SILVA, A.M.; SOUTO, E.B.; GREMIÃO, M.P.D. Development of Solid Lipid Nanoparticles for Praziquantel Delivery: Particle Size Characterization and Cell Toxicity Assessment. Sci. Pharm. 2010, 78, 576. https://doi.org/10.3797/scipharm.cespt.8.LNT02
SOUZA ALR, ANDREANI T, DOKTOROVOVÁ S, SILVA AM, SOUTO EB, GREMIÃO MPD. Development of Solid Lipid Nanoparticles for Praziquantel Delivery: Particle Size Characterization and Cell Toxicity Assessment. Scientia Pharmaceutica. 2010; 78(3):576. https://doi.org/10.3797/scipharm.cespt.8.LNT02
Chicago/Turabian StyleSOUZA, A. L. R., T. ANDREANI, S. DOKTOROVOVÁ, A. M. SILVA, E. B. SOUTO, and M. P. D. GREMIÃO. 2010. "Development of Solid Lipid Nanoparticles for Praziquantel Delivery: Particle Size Characterization and Cell Toxicity Assessment" Scientia Pharmaceutica 78, no. 3: 576. https://doi.org/10.3797/scipharm.cespt.8.LNT02
APA StyleSOUZA, A. L. R., ANDREANI, T., DOKTOROVOVÁ, S., SILVA, A. M., SOUTO, E. B., & GREMIÃO, M. P. D. (2010). Development of Solid Lipid Nanoparticles for Praziquantel Delivery: Particle Size Characterization and Cell Toxicity Assessment. Scientia Pharmaceutica, 78(3), 576. https://doi.org/10.3797/scipharm.cespt.8.LNT02